A Pathology News report on a Mayo Clinic study in Respiratory Research brings spatial profiling back to a practical question for pathologists: is it enough to know the cell type, or do we also need to know where the cell sits and which cells surround it? In chronic airway disease, location does not look like a minor detail. The analysis showed that asthma and COPD differ not only in the amount of inflammation or the degree of fibrosis, but also in how immune and structural cells are arranged within distinct cellular neighborhoods.
The Mayo Clinic team used the Akoya PhenoCycler-Fusion platform to study lung samples from 17 people: five without asthma, four with asthma, and eight with chronic obstructive pulmonary disease. The panel included 10 markers, including CD45, CD3, CD4, and CD8 for immune cells; E-cadherin, smooth muscle actin, and collagen for structural components; Ki67 and PCNA for proliferation; and CD34 for vascular assessment. This is not a large cohort by case number, but it gives a clear example of what is added when a cell is read in its native position rather than as a number separated from the tissue.
The finding that matters for pathologists
The most important point in the study is that asthma showed a clearer role for CD8+ T cells than is often assumed when the disease is viewed only through a Th2 or eosinophil lens. This does not discard the established models. It adds a spatial layer: where are these cells located? Which cells are they adjacent to? Do they appear near epithelium, smooth muscle, or areas of remodeling? These questions are closer to the language of pathology than to abstract genomic tables.
In COPD, regions rich in extracellular matrix stood out. Niches dominated by collagen or structural change may help explain why treatment response differs among patients who share the same clinical diagnosis. For the practicing pathologist, the value is not only in naming a new pattern. It is in thinking of a biopsy or resection specimen as a possible therapeutic map, especially when discussing anti-fibrotic strategies or selecting patients for clinical trials.
Why isolated cells are not enough
The study points back to a known limitation of single-cell analyses: isolating the cell gives high detail, but removes the neighborhood that gives that detail meaning. In the lung, epithelium, smooth muscle, fibroblasts, vessels, and immune cells act within a three-dimensional structure. When we separate them completely, part of the disease behavior is lost. Spatial profiling puts some of that context back into the analysis.
This matters in diseases that are not distributed evenly through tissue. A small area around a bronchiole may be more informative than the average of the whole sample. A general quantitative readout may also hide a local cluster of CD8+ T cells or a fibrotic edge related to obstruction. Multiplex imaging therefore looks useful when the question is anatomical and immunologic at the same time, not when the goal is just a cell count.
Reading the study through daily practice
The study should not be asked to do more than it can. The sample size is limited, and it does not provide a test ready for routine use tomorrow morning. It does, however, point to a direction that deserves close follow-up: turning the histologic image from a morphologic description into a measurement of spatial relationships. That is exactly where pathologists can add value that molecular analysis alone cannot provide.
In a conventional report, we note inflammation, fibrosis, smooth muscle hypertrophy, or epithelial change. In a spatial reading, these elements can be connected to each other: are T cells present within defined fibrotic regions? Is epithelial proliferation linked to local vascularity? Does immune-cell distribution differ between asthma and COPD in a measurable way? Questions like these may later become part of therapeutic study design or more precise tissue-based classification models.
A clearer link to digital transformation in pathology
This is not about digitizing a slide for easier archiving or remote viewing. The real value appears when WSI becomes the first layer in a multi-marker analysis, where immune signal is connected to tissue architecture and location. This kind of work needs strict pre-analytic control: specimen type, fixation, section quality, choice of regions of interest, and consistent reading across cases. Any failure in those steps can appear as a false spatial signal.
A 10-marker panel also forces tradeoffs. Every marker included in the panel takes space from another question. Design should therefore start from the disease hypothesis, not from antibody availability or the appeal of the technology. In this study, combining immune, structural, proliferation, and vascular markers makes sense because it matches the question of airway remodeling and chronic inflammation.
What should be watched next?
The first real test of these findings will be replication in larger numbers, with clearer clinical stratification and links to respiratory function, disease severity, and prior treatment. We also need to know whether the detected cellular neighborhoods remain stable across different centers and preparation methods. Without that, the result will remain research-relevant but insufficient to change clinical decisions.
Readability is another issue. If the analysis requires a long chain of computational processing that cannot be reviewed, it will be hard to bring into a diagnostic setting. If it can be presented as a clear measurement structure, with maps that pathologists can review and connect to histology, it moves closer to practice. The pathologist should stay at the center of tool design, not appear at the end of the chain as a user who only presses run.
Practical bottom line
The study does not say that every case of asthma or COPD needs multi-marker spatial analysis. It says something more specific: in chronic airway disease, the distribution of cells within tissue may explain differences that cell counts alone do not show. That opens a path toward more measurable pulmonary pathology, especially in research specimens and therapeutic trials.
For pathologists, the message is straightforward. As spatial biology enters the laboratory, judging tissue quality, choosing the region to read, and interpreting the relationship between cell and structure will become central parts of professional value. The technology measures. Meaning still needs a trained eye that understands the tissue before trusting the map.
Source: Pathology News.